Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 21, 2019; 25(15): 1840-1853
Published online Apr 21, 2019. doi: 10.3748/wjg.v25.i15.1840
Published online Apr 21, 2019. doi: 10.3748/wjg.v25.i15.1840
Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data
Gui-Fang Guo, Yi-Xing Wang, Xiu-Xing Chen, Hao-Hua Wang, Chang Jiang, Hui-Quan Qiu, Liang-Ping Xia, VIP Department, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Gui-Fang Guo, Yi-Xing Wang, Yi-Jun Zhang, Xiu-Xing Chen, Jia-Bin Lu, Hao-Hua Wang, Chang Jiang, Hui-Quan Qiu, Liang-Ping Xia, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Gui-Fang Guo, Yi-Xing Wang, Yi-Jun Zhang, Xiu-Xing Chen, Jia-Bin Lu, Hao-Hua Wang, Chang Jiang, Hui-Quan Qiu, Liang-Ping Xia, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, Guangdong Province, China
Yi-Jun Zhang, Jia-Bin Lu, Pathology Department, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Author contributions: Guo GF designed the research; Guo GF and Wang YX analyzed the data and wrote the paper; Chen XX and Wang HH performed the experiments; Zhang YJ and Lu JB contributed new reagents and analytic tools; Jiang C and Qiu HQ collected the data; Xia LP amended the paper; all of the authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the Ethics Committee of the Sun Yat-sen University Cancer Center, Guangdong, China. All patients involved in this study gave their informed consent for participation in the study.
Conflict-of-interest statement: The authors have no conflict of interest relevant to this study.
Data sharing statement: The manuscript has no additional data available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Gui-Fang Guo, MD, PhD, Professor, VIP Department, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, Guangdong Province, China. guogf@sysucc.org.cn
Telephone: +86-20-87342708 Fax: +86-20-87342708
Received: January 24, 2019
Peer-review started: January 24, 2019
First decision: February 26, 2019
Revised: March 20, 2019
Accepted: March 24, 2019
Article in press: March 25 2019
Published online: April 21, 2019
Peer-review started: January 24, 2019
First decision: February 26, 2019
Revised: March 20, 2019
Accepted: March 24, 2019
Article in press: March 25 2019
Published online: April 21, 2019
Core Tip
Core tip: Considering the response rate to cetuximab in advanced colorectal cancer patients with wild-type KRAS, autophagy might be a novel predictor to exclude patients who will not respond to cetuximab. Accordingly, Beclin1, microtubule-associated protein 1A/B-light chain 3 (LC3), and 4E-binding protein 1 (4E-BP1) were studied in this research. We found that LC3 was overexpressed in tumor tissues, and the expression levels of Beclin1 and 4E-BP1 were related to overall survival.